Financing Available For Some, But Not All Biopharma Companies In 2023

Firms With No Near-Term Milestones Could Shutter

Investors, advisors and CEOs at the J.P. Morgan Healthcare Conference and Biotech Showcase were somewhat optimistic about fundraising this year, but noted certain companies may have to call it quits.

2023 New year card background economy finance business investment concept
2023 should be a good year for financing for companies that execute well • Source: Shutterstock

The biopharmaceutical industry still has a long way to go to recover from valuation declines that began in 2021, but signs of improving health in the sector in late 2022 and unchanged business fundamentals offer hope that many companies will be able to access funding to advance drug development programs and commercialize approved medicines in 2023. Observers acknowledge, however, that the trend of some firms shutting down due to dwindling cash will continue.

The key to new financing will be achieving a major clinical or regulatory milestone – or at least the promise...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.